Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 9/20 | 0.64 |
| ▸ | GSK3B | P49841 | 8/20 | 0.64 |
| ▸ | CDK2 | P24941 | 4/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw708336X SCHEMBL4463359 | 0.78 | CDK4 (1.00) | CDK4GSK3BCDK2 | |
| SCHEMBL4477329 | 0.77 | DYRK1A (0.49) | CDK4GSK3BCDK2DYRK1AALDH1A1 | |
| SCHEMBL4480449 | 0.76 | GSK3B (0.70) | CDK4GSK3BCDK2DYRK1A | |
| SCHEMBL4475377 | 0.75 | DYRK1A (0.69) | CDK4GSK3BCDK2DYRK1A | |
| SCHEMBL5659235 | 0.75 | GSK3B (0.64) | CDK4GSK3BCDK2DYRK1A | |
| SCHEMBL28322120 | 0.73 | ALDH1A1 (0.65) | ALDH1A1LMNAGAAMAPTSMN1; SMN2 | |
| SCHEMBL4488276 | 0.73 | DYRK1A (0.65) | CDK4GSK3BCDK2DYRK1A | |
| SCHEMBL5946375 | 0.73 | DYRK1A (0.39) | CDK4GSK3BCDK2DYRK1A | |
| SCHEMBL4474975 | 0.73 | CDK4 (0.61) | CDK4GSK3BCDK2DYRK1AALDH1A1 | |
| SCHEMBL4476755 | 0.68 | CDK4 (1.00) | CDK4GSK3BCDK2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-7279473-B2 | Pyrazolopyridazine derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1463730-B1 | PYRAZOLOPYRIDAZINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-1551842-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050090507-A1 | Pyrazolopyridazine derivatves | SMITHKLINE BEECHAM CORPORATION | 2005-04-28 | — | — | US | disclosed |
| EP-1463730-A1 | PYRAZOLOPARIDAZINE DERIVATIVES | SmithKline Beecham Corporation (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003051886-A1 | PYRAZOLOPYRIDAZINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090507-A1 | Pyrazolopyridazine derivatves | CDK4, CDK3, CDK8 | CDK4 1/4885GSK3B 1622/4885CDK2 8/4885 |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | CDK4 218/4885GSK3B 1/4885CDK2 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.